Jiangsu Lianhuan Pharmaceutical Co Ltd

SHG:600513 China Drug Manufacturers - Specialty & Generic
Market Cap
$836.85 Million
CN¥6.14 Billion CNY
Market Cap Rank
#10359 Global
#2276 in China
Share Price
CN¥21.51
Change (1 day)
-3.46%
52-Week Range
CN¥8.74 - CN¥29.47
All Time High
CN¥29.47
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Jiangsu Lianhuan Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceuticals, preparations, and active pharmaceutical ingredients (API) products in China and internationally. The company offers clopidogrel bisulfate tablets, doxycycline hydrochloride, azithromycin, milrinone, dapoxetine hydrochloride, tadalafil, and betasine besylate tablets, as well as aprili… Read more

Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) - Net Assets

Latest net assets as of September 2025: CN¥1.74 Billion CNY

Based on the latest financial reports, Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) has net assets worth CN¥1.74 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.11 Billion) and total liabilities (CN¥2.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥1.74 Billion
% of Total Assets 42.28%
Annual Growth Rate 14.99%
5-Year Change 33.43%
10-Year Change 103.54%
Growth Volatility 38.58

Jiangsu Lianhuan Pharmaceutical Co Ltd - Net Assets Trend (2000–2024)

This chart illustrates how Jiangsu Lianhuan Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Jiangsu Lianhuan Pharmaceutical Co Ltd (2000–2024)

The table below shows the annual net assets of Jiangsu Lianhuan Pharmaceutical Co Ltd from 2000 to 2024.

Year Net Assets Change
2024-12-31 CN¥1.58 Billion +3.95%
2023-12-31 CN¥1.52 Billion +7.33%
2022-12-31 CN¥1.41 Billion +10.37%
2021-12-31 CN¥1.28 Billion +8.37%
2020-12-31 CN¥1.18 Billion +9.04%
2019-12-31 CN¥1.08 Billion +14.52%
2018-12-31 CN¥946.61 Million +7.79%
2017-12-31 CN¥878.23 Million +6.16%
2016-12-31 CN¥827.25 Million +6.76%
2015-12-31 CN¥774.88 Million +78.44%
2014-12-31 CN¥434.25 Million +7.99%
2013-12-31 CN¥402.11 Million +14.75%
2012-12-31 CN¥350.42 Million +6.96%
2011-12-31 CN¥327.61 Million +6.04%
2010-12-31 CN¥308.95 Million +5.12%
2009-12-31 CN¥293.89 Million +4.33%
2008-12-31 CN¥281.68 Million +4.34%
2007-12-31 CN¥269.97 Million +4.16%
2006-12-31 CN¥259.20 Million +1.26%
2005-12-31 CN¥255.97 Million +2.22%
2004-12-31 CN¥250.42 Million +1.71%
2003-12-31 CN¥246.22 Million +188.78%
2002-12-31 CN¥85.26 Million +22.70%
2001-12-31 CN¥69.48 Million +25.97%
2000-12-31 CN¥55.16 Million --

Equity Component Analysis

This analysis shows how different components contribute to Jiangsu Lianhuan Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 17010.2% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥745.19 Million 53.40%
Common Stock CN¥285.46 Million 20.45%
Other Comprehensive Income CN¥107.70 Million 7.72%
Other Components CN¥257.26 Million 18.43%
Total Equity CN¥1.40 Billion 100.00%

Jiangsu Lianhuan Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Jiangsu Lianhuan Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Dianguang Explosion-proof Technology Co Ltd
SHE:002730
 		$491.99 Million
Matas A/S
CO:MATAS
 		$492.09 Million
Rocket Internet SE
HM:RKET
 		$492.11 Million
CH. Karnchang PCL
BK:CK
 		$492.20 Million
Rayonier Advanced Materials
NYSE:RYAM
 		$491.82 Million
Shanghai Anoky Group
SHE:300067
 		$491.80 Million
Shanghai Hugong Elec(Group)
SHG:603131
 		$491.70 Million
Ingram Micro Holding Corporation
NYSE:INGM
 		$491.62 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jiangsu Lianhuan Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,354,189,000 to 1,395,610,000, a change of 41,421,000 (3.1%).
  • Net income of 84,160,000 contributed positively to equity growth.
  • Dividend payments of 50,565,000 reduced retained earnings.
  • Other comprehensive income increased equity by 8,495,598.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥84.16 Million +6.03%
Dividends Paid CN¥50.56 Million -3.62%
Other Comprehensive Income CN¥8.50 Million +0.61%
Other Changes CN¥-669.60K -0.05%
Total Change CN¥- 3.06%

Book Value vs Market Value Analysis

This analysis compares Jiangsu Lianhuan Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.47x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 99.72x to 4.47x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2000-12-31 CN¥0.22 CN¥21.51 x
2001-12-31 CN¥0.27 CN¥21.51 x
2002-12-31 CN¥0.33 CN¥21.51 x
2003-12-31 CN¥0.96 CN¥21.51 x
2004-12-31 CN¥0.98 CN¥21.51 x
2005-12-31 CN¥0.99 CN¥21.51 x
2006-12-31 CN¥1.00 CN¥21.51 x
2007-12-31 CN¥1.01 CN¥21.51 x
2008-12-31 CN¥1.12 CN¥21.51 x
2009-12-31 CN¥1.47 CN¥21.51 x
2010-12-31 CN¥1.17 CN¥21.51 x
2011-12-31 CN¥1.66 CN¥21.51 x
2012-12-31 CN¥1.45 CN¥21.51 x
2013-12-31 CN¥1.49 CN¥21.51 x
2014-12-31 CN¥1.63 CN¥21.51 x
2015-12-31 CN¥2.73 CN¥21.51 x
2016-12-31 CN¥2.90 CN¥21.51 x
2017-12-31 CN¥3.11 CN¥21.51 x
2018-12-31 CN¥3.29 CN¥21.51 x
2019-12-31 CN¥3.47 CN¥21.51 x
2020-12-31 CN¥3.75 CN¥21.51 x
2021-12-31 CN¥4.06 CN¥21.51 x
2022-12-31 CN¥4.44 CN¥21.51 x
2023-12-31 CN¥4.71 CN¥21.51 x
2024-12-31 CN¥4.81 CN¥21.51 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jiangsu Lianhuan Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 6.03%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 3.90%
  • • Asset Turnover: 0.72x
  • • Equity Multiplier: 2.16x
  • Recent ROE (6.03%) is below the historical average (8.22%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2000 13.17% 11.23% 0.62x 1.88x CN¥1.75 Million
2001 19.64% 19.71% 0.60x 1.66x CN¥6.70 Million
2002 18.50% 20.09% 0.62x 1.48x CN¥7.25 Million
2003 4.58% 10.01% 0.38x 1.19x CN¥-13.30 Million
2004 2.91% 4.01% 0.58x 1.25x CN¥-17.72 Million
2005 2.98% 4.38% 0.57x 1.20x CN¥-17.82 Million
2006 3.04% 4.71% 0.49x 1.30x CN¥-17.91 Million
2007 3.80% 5.21% 0.54x 1.34x CN¥-16.57 Million
2008 4.69% 5.83% 0.63x 1.28x CN¥-14.88 Million
2009 5.87% 6.62% 0.68x 1.31x CN¥-12.11 Million
2010 6.59% 7.03% 0.72x 1.30x CN¥-10.52 Million
2011 7.49% 7.56% 0.77x 1.28x CN¥-8.21 Million
2012 7.59% 8.81% 0.73x 1.17x CN¥-9.09 Million
2013 9.54% 6.15% 0.96x 1.62x CN¥-1.84 Million
2014 10.14% 6.58% 1.01x 1.52x CN¥602.50K
2015 6.47% 7.80% 0.64x 1.29x CN¥-27.30 Million
2016 7.58% 10.36% 0.57x 1.29x CN¥-19.98 Million
2017 8.03% 10.24% 0.59x 1.33x CN¥-17.26 Million
2018 7.91% 7.22% 0.72x 1.53x CN¥-19.47 Million
2019 8.06% 6.18% 0.68x 1.91x CN¥-19.19 Million
2020 9.61% 7.43% 0.68x 1.91x CN¥-4.15 Million
2021 10.26% 7.22% 0.70x 2.03x CN¥3.03 Million
2022 11.16% 7.23% 0.72x 2.14x CN¥14.71 Million
2023 9.97% 6.21% 0.76x 2.11x CN¥-409.90K
2024 6.03% 3.90% 0.72x 2.16x CN¥-55.40 Million

Industry Comparison

This section compares Jiangsu Lianhuan Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Jiangsu Lianhuan Pharmaceutical Co Ltd (600513) CN¥1.74 Billion 13.17% 1.37x $491.98 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million